Skip to main content
NAVCO Pharmaceuticals logo

NAVCO Pharmaceuticals — Investor Relations & Filings

Ticker · NAV ISIN · CA63942R1091 LEI · 8945003WKDH61M8UB963 TSXV Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2024-01-30 Regulatory Filings
Country CA Canada
Listing TSXV NAV

About NAVCO Pharmaceuticals

https://www.navcopharma.com/

NAVCO Pharmaceuticals is a biotechnology company specializing in the research, development, and commercialization of nanotechnology products and materials. The company utilizes proprietary Computerized Nano-meter Algorithms to create innovative solutions for anti-viral, anti-fungal, and anti-bacterial treatments. NAVCO focuses on developing supplemental and therapeutic consumer health and wellness products. A key offering is the BioActive™ line, which includes non-toxic, non-flammable, and alcohol-free hand cleansers, creams, and surface disinfectants designed to provide extended protection against germs and microorganisms. These nanotechnology products are marketed across various sectors, including medicine and textiles, providing next-generation protection solutions for multiple industries.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV1 Certification of Annual Filings by the CEO of Navco Pharmaceuticals Inc. It certifies the review and fair presentation of the annual filings for the financial year ended September 30, 2023. The document is a certification letter, not the actual annual report or financial statements. It explicitly states it is a Venture Issuer Basic Certificate under National Instrument 52-109, which is a regulatory certification. The document length is short (3136 characters) and it does not contain financial data or the report itself, only a certification of the filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the report they reference.
2024-01-30 English
Annual MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management Discussion & Analysis' (MD&A) for the year ended September 30, 2023, prepared by NAVCO Pharmaceuticals Inc. It contains detailed explanations of the company's financial performance, operations, liquidity, capital resources, related party transactions, financial risks, and accounting policies. The document includes financial data and analysis for the fiscal year, quarterly summaries, and forward-looking statements. It is not a brief announcement or a certification letter, but a comprehensive management report discussing financial results and business trends. Therefore, it fits the definition of a Management Reports (MDA) filing.
2024-01-30 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 95% confidence The document is a Form 13-501F1 related to participation fees for reporting issuers, submitted to the Alberta Securities Commission. It includes a management certification by the CFO, market value calculations for specified trading periods, and fee details. The document is a regulatory filing form with certification and fee calculation, not a financial report or earnings release. It is primarily a management certification and fee submission form, which fits best under Regulatory Filings (RNS) as it does not contain financial statements or detailed financial analysis but is a compliance filing with certification.
2024-01-30 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 95% confidence The document is titled 'FORM 13-502F1' and is a Management Certification related to participation fees for Class 1 and Class 3B reporting issuers, submitted to the Ontario Securities Commission. It contains detailed calculations of market value of securities for quarterly periods and fee amounts payable. The document is a certification by an officer (CFO) confirming the accuracy of the information provided. It does not contain financial statements or substantive financial data typical of an Annual Report or Interim Report. It is primarily a regulatory filing with certification and fee calculation information. Therefore, it fits best under Regulatory Filings (RNS).
2024-01-30 English
Audited annual financial statements – English.pdf
Annual Report Classification · 100% confidence The document is an Independent Auditor's Report for NAVCO Pharmaceuticals Inc. for the fiscal year ended September 30, 2023. It includes the auditor's opinion, basis for opinion, key audit matters, and detailed financial statements such as the statements of financial position, loss and comprehensive loss, changes in equity, and cash flows. The presence of detailed financial statements and the auditor's report indicates this is a full annual financial report. The document length is 15,000 characters, which is consistent with a full report rather than a brief announcement. The content and structure align with an Annual Report (10-K) filing, which covers the company's full financial performance and activity for the year. Therefore, the correct classification is Annual Report (10-K). FY 2023
2024-01-30 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed by Navco Pharmaceuticals Inc. It details a material change event, specifically the acquisition of SL Immuno Pharma Corp., including share issuance and changes in the board of directors. The document is structured as a regulatory disclosure of a material corporate event rather than a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on the announcement of a significant corporate transaction and related governance changes. This type of filing aligns with regulatory announcements of material changes rather than annual or quarterly reports, earnings releases, or management discussions. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-29 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.